Current Issue : April - June Volume : 2018 Issue Number : 2 Articles : 1 Articles
The present study has been undertaken to investigate the renoprotective effect of omeprazole in streptozotocin-induced diabetic nephropathy in Wistar rats. Diabetic nephropathy was induced with a single injection of streptozotocin (STZ, 45 mg/kg, i.p.). Omeprazole (20 mg/kg; 40 mg/kg, p.o.; 4 weeks) was administered to diabetic rats after 4 weeks of STZ treatment. A battery of biochemical tests such as serum glucose, glycated hemoglobin, blood urea nitrogen (BUN), serum creatinine, albumin and kidney weight/ body weight (%) ratio were performed to evaluate the renal functions. Oxidative stress was determined by estimating renal thiobarbituric acid reactive species (TBARS) and reduced glutathione (GSH) levels. Lipid profile was assessed by determining serum cholesterol (TC), triglyceride (TG) and high density lipoprotein (HDL). The STZ-treated rats demonstrated deleterious alterations in kidney functions, enhanced oxidative stress and disturbed lipid profile. Administration of omeprazole to diabetic rats significantly reduced serum glucose, glycated hemoglobin, BUN, creatinine, albumin levels and oxidative stress. Serum lipids like TC and TG were decreased and HDL was enhanced in omeprazole-treated STZ rats. The findings of our study indicate that renoprotective effects of omeprazole may be attributed to its glucose-lowering, lipid-lowering and antioxidative potential....
Loading....